Accepted for/Published in: JMIR Research Protocols
Date Submitted: Sep 27, 2025
Open Peer Review Period: Sep 29, 2025 - Nov 24, 2025
Date Accepted: May 18, 2026
Date Submitted to PubMed: May 18, 2026
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Lymphovenous Bypass as an Adjunct to Standard Care for Diabetic Peripheral Neuropathy: Protocol for a Randomized, Assessor-Blinded Superiority Trial
ABSTRACT
Background:
Diabetic peripheral neuropathy (DPN) is a length-dependent, symmetric sensorimotor polyneuropathy with substantial global and regional burden. Current pharmacologic options are largely symptomatic and do not modify disease. Lymphovenous bypass (LVB), a supermicrosurgical procedure established for lymphedema, may modulate lymphatic-immune-microvascular dysfunction relevant to DPN
Objective:
The primary objective is to determine whether lymphovenous bypass (LVB) combined with standard of care (SOC) improves small-fiber and autonomic function compared with SOC alone at 6 months. Secondary objectives are to evaluate the effects of LVB on large-fiber function, neuropathic pain, ulcer healing, quality of life, and relevant biomarkers, as well as to characterize its safety profile.
Methods:
SPIRIT-aligned, single-center, randomized, controlled, parallel-group superiority trial with 2:1 allocation (LVB+SOC:SOC), stratified by ulcer status. Outcome assessors and statisticians are blinded. Primary endpoint is change in pain (DN4) and DPN burden (MNSI), at 6 and 12 months. Key secondary endpoints include foot electrochemical skin conductance (ESC, µS; Sudoscan), nerve conduction studies (NCS), and ulcer outcomes (time to epithelialization; proportion healed by 20 weeks; infection; reoperation; amputation). Exploratory endpoints include oxidative stress/antioxidant indices, inflammatory cytokines, and intraepidermal nerve fiber density (IENFD). N = 60 (LVB n = 40; SOC n = 20) provides 80% power (α = 0.05) to detect a conservative between-group ESC effect (Cohen’s d ≈ 0.70).
Results:
Recruitment is planned for September 1, 2025–July 31, 2026; follow-up through July 31, 2027. No outcome data are included.
Conclusions:
This trial tests a mechanism-based, non-pharmacologic adjunct targeting lymphatic-immune-microvascular dysfunction in DPN. If effective, LVB could inform phenotype-directed treatment algorithms and motivate multicenter evaluation and health-economic analyses. Clinical Trial: NCT07126197
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.